Crescent Biopharma (CBIO) Stock Statistics & Valuation Metrics

Crescent Biopharma has a market cap or net worth of $260.41M. The enterprise value is $116.16M.

Crescent Biopharma has 27,556,767 shares outstanding. The number of shares has decreased by -2.65% in one year.

Crescent Biopharma’s return on equity (ROE) is -13.45 and return on invested capital (ROIC) is -263.77%.

The current PE Ratio of Crescent Biopharma is ―. Crescent Biopharma’s PEG ratio is -13.03.

In the last 12 months, Crescent Biopharma had revenue of 0.00 and earned -71.47M in profits. Earnings per share was -0.59.

In the last 12 months, operating cash flow was -48.49M and capital expenditures -726.00K, giving a free cash flow of -49.22M billion.

Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―

Crescent Biopharma upcoming earnings date is Apr 30, 2026, After Close (Confirmed).

Crescent Biopharma as a current ratio of 3.62, with Debt / Equity ratio of 2.63%

In the past 12 months, Crescent Biopharma has paid 0.00 in taxes.

Crescent Biopharma EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -51.70.

Crescent Biopharma has $133.26M in cash and marketable securities with $3.06M in debt, giving a net cash position of $130.20M billion.

Gross margin is 94.76%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Crescent Biopharma is $31.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy